Fig. 1: Changes in echocardiographic parameters from baseline to month 30 in the vutrisiran versus placebo groups in the overall and monotherapy populations. | Nature Medicine

Fig. 1: Changes in echocardiographic parameters from baseline to month 30 in the vutrisiran versus placebo groups in the overall and monotherapy populations.

From: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial

Fig. 1

a–h, LS mean changes in mean LV wall thickness (a), LV mass index (b), lateral e’ velocity (c), lateral E/e’ (d), LVEF (e), absolute GLS (f), LV stroke volume (g) and RV S’ (h) from baseline to month 30 for vutrisiran versus placebo for the overall and monotherapy populations. Dots represent the LS mean change from baseline to month 30 and the error bars represent the s.e.m. Sample size for each echocardiographic parameter can be found in Table 2.

Back to article page